Close

UPDATE: Benchmark Starts Belite Bio, Inc, ADR (BLTE) at Buy, 'A Novel Approach to Macular Degeneration'

Go back to UPDATE: Benchmark Starts Belite Bio, Inc, ADR (BLTE) at Buy, 'A Novel Approach to Macular Degeneration'
(NASDAQ: BLTE) Delayed: 28.79 +0.23 (0.81%)
Previous Close $28.56    52 Week High
Open $27.42    52 Week Low
Day High $29.49    P/E N/A 
Day Low $27.40    EPS
Volume 37,204